IGM Biosciences, Inc. (IGMS)
Au 14, 2025 - IGMS was delisted (reason: acquired by Concentra Biosciences)
1.270
-0.030 (-2.31%)
Inactive · Last trade price on Aug 13, 2025
Company Description
IGM Biosciences, Inc., a biotechnology company, develops Immunoglobulin M antibodies for the treatment of cancer and autoimmune and inflammatory diseases.
The company was formerly known as Palingen, Inc. and changed its name to IGM Biosciences, Inc. in 2010.
IGM Biosciences, Inc. was incorporated in 1993 and is headquartered in Mountain View, California. As of August 14, 2025, IGM Biosciences, Inc. operates as a subsidiary of Concentra Biosciences, LLC.
IGM Biosciences, Inc.
| Country | United States |
| Founded | 1993 |
| IPO Date | Sep 18, 2019 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 149 |
| CEO | Mary Harler |
Contact Details
Address: 325 East Middlefield Road Mountain View, Delaware 94043 United States | |
| Phone | 650 965 7873 |
| Website | igmbio.com |
Stock Details
| Ticker Symbol | IGMS |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $16.00 |
| CIK Code | 0001496323 |
| CUSIP Number | 449585108 |
| ISIN Number | US4495851085 |
| Employer ID | 77-0349194 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Mary Beth Harler M.D. | Chief Executive Officer and Director |
| Paul C. Graffagnino J.D. | Senior Vice President of Legal Affairs |
| Suzette Tauber | Chief Human Resources Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 15, 2025 | SCHEDULE 13D/A | Filing |
| Aug 14, 2025 | EFFECT | Notice of Effectiveness |
| Aug 14, 2025 | EFFECT | Notice of Effectiveness |
| Aug 14, 2025 | EFFECT | Notice of Effectiveness |
| Aug 14, 2025 | EFFECT | Notice of Effectiveness |
| Aug 14, 2025 | EFFECT | Notice of Effectiveness |
| Aug 14, 2025 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Aug 14, 2025 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Aug 14, 2025 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Aug 14, 2025 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |